Skip to main content
SpringerLink
Log in

Treatment of Chronic Hepatitis C in “Difficult-to-Treat” Patients in the Clinical Setting

  • Chapter
Hepatitis C Virus Disease

  • 652 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Akuta, N., Suzuki, F., Suzuki, Y., Sezaki, H., Hosaka, T., Someya, T., Kobayashi, M., Saitoh, S., Arase, Y., Ikeda, K., Kobayashi, M., Kumada, H. (2005). Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients with HCV genotype 2a: virological features of IFN-resistant cases with hepatocyte steatosis. Journal of Medical Virology, 75: 550–558.

    Article  PubMed  CAS  Google Scholar 

  • Akuta, N., Suzuki, F., Sezaki, H., Suzuki, Y., Hosaka, T., Someya, T., Kobayashi, M., Saitoh, S., Watahiki, S., Sato, J., Kobayashi, M., Arase, Y., Ikeda, K., Kumada, H. (2006). Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. Journal of Medical Virology, 78: 83–90.

    Article  PubMed  CAS  Google Scholar 

  • Anonymous. (1999). Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Journal of Viral Hepatitis, 6: 35–47.

    Google Scholar 

  • Ball, L.M., Sulkowski, M.S., Wolf, L, Weiz, K.B., Tice, A.D, Dieterich, D.T. (1999). Filgrastim use for interferon induced neutropenia in patients with hepatitis C (abstract). Gastroenterology, 116: A1188.

    Google Scholar 

  • Bárcena, R., Gil-Grande, L., Moreno, J., Foruny, J.R., Otón, E., García, M., Blázquez, J., Sánchez, J., Moreno, A., Moreno, A. (2005). Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin. Tranplantation, 79: 1634–1635.

    Article  Google Scholar 

  • Bárcena, R., Moreno, A., Foruny, J.R., Moreno, A., Sánchez, J., Gil-Grande, L., Blázquez, J., Nuño, J., Fortún, J., Rodriguez-Gandía, M.A., Otón, E. (2006). Improved graft function in liver-transplanted patients after partial splenic embolization: reversal of splenic artery steal syndrome? Clinical Transplantation, 20: 517–522.

    Article  PubMed  Google Scholar 

  • Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., Poynard, T. (1999). Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology, 30: 1054–1058.

    Article  PubMed  CAS  Google Scholar 

  • Benhamou, Y., Di Martino, V., Bochet, M., Colombert, G., Thibault, V., Liou, A., Katlama, C., Poynard, T.; Multivirc Group (2001). Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-co-infected patients: impact of protease inhibitor therapy. Hepatology, 34: 283–287.

    Article  PubMed  CAS  Google Scholar 

  • Berenguer, M (2005). What determines the natural history of recurrent hepatitis C after liver transplantation? Journal of Hepatology, 42: 448–456.

    Article  PubMed  Google Scholar 

  • Berenguer, M., Ferrell, L., Watson, J., Prieto, M., Kim, M., Rayon, M., Cordoba, J., Herola, A., Ascher, N., Mir, J., Berenguer, J., Wright, T.L. (2000). HCV-related fibrosis progression following liver transplantation: increase in recent years. Journal of Hepatology, 32: 673–684.

    Article  PubMed  CAS  Google Scholar 

  • Berg, T., von Wagner, M., Nasser, S., Sarrazin, C., Heintges, T., Gerlach, T., Buggisch, P., Goeser, T., Rasenack, J., Pape, G.R., Schmidt, W.E., Kallinowski, B., Klinker, H., Splenger, U., Martus, P., Alshuth, U., Zeuzem, S. (2006). Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alpha-2a plus ribavirin. Gastroenterology, 130: 1086–1097.

    Article  PubMed  CAS  Google Scholar 

  • Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R., Snydman, D.R. (2001). Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clinical Infectious Diseases, 32: 492–497.

    Article  PubMed  CAS  Google Scholar 

  • Biggins, S.W., Terrault, N.A. (2005). Treatment of recurrent hepatitis C after liver transplantation. Clinics in Liver Disease, 9 : 505–523.

    Article  PubMed  Google Scholar 

  • Bizollon, T., Palazzo, U., Ducerf, C., Chevallier, M., Elliot, M., Baulieux, J., Pouyet, M., Trepo, C. (1997). Pilot study of the combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology, 26: 500–504.

    Article  PubMed  CAS  Google Scholar 

  • Bonacini, M., Govindarajan, S., Blatt, L.M., Schmid, P., Conrad, A., Lindsay, K.L. (1999). Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. Journal of Viral Hepatitis, 6: 203–208.

    Article  PubMed  CAS  Google Scholar 

  • Brady, C.W., Muir, A.J. (2005). HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology, 42: 496–497.

    Article  PubMed  Google Scholar 

  • Bruno, S., Cammá, C., Di Marco, V., Rumi, M., Vinci, M., Camozzi, M., Rebucci, C., Di Bona, D., Colombo, M., Craxi, A., Mondelli, M.U., Pinzello, G. (2004). Peginterferon alpha-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Journal of Hepatology, 41: 474–481.

    Article  PubMed  CAS  Google Scholar 

  • Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Morand, P., Goujard, C., Pialoux, G., Piroth, L., Salmon-Ceron, D., Degott, C., Cacoub, P., Perrone, C., ANRS HCO2 RIBAVIC Study Team (2004). Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavirin for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Journal of the American Medical Association, 292: 2839–2848.

    Article  PubMed  CAS  Google Scholar 

  • Chalasani, N., Manzarbeitia, C., Ferenci, P., Vogel, W., Fontana, R.J., Voigt, M., Riely, C., Martin, P., Teperman, L., Jiao, J., Lopez-Talavera, J.C., Pegasys Transplant Study Group (2005). Peginterferon alpha-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology, 41: 289–298.

    Article  PubMed  CAS  Google Scholar 

  • Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244: 359–362.

    Article  PubMed  CAS  Google Scholar 

  • Chung, R.T., Andersen, J., Volberding, P., Robbins, G.K., Liu, T., Sherman, K.E., Peters, M.G., Koziel, M.J., Bhan, A.K., Alston, B., Colquhoun, D., Nevin, T., Harb, G., van der Horst, C., AIDS Clinical Trials Group A5071 Study Team (2004). Peginterferon alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351: 451–459.

    Article  PubMed  CAS  Google Scholar 

  • Craxi, A, Camma, C. (2006). Treating patients with HCV genotype 1 and low viraemia: more than meets the eye. Journal of Hepatology, 44: 4–7.

    Article  PubMed  Google Scholar 

  • Cribier, B., Rey, D., Schmitt, C., Lang, J.M., Kirn, A., Stoll-Keller, F. (1995). High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS, 9: 1131–1136.

    Article  PubMed  CAS  Google Scholar 

  • Curry, M., Cárdenas, A., Afdhal, N.H. (2005). Effect of maintenance Peg-Interferon therapy on portal hypertension and its complications: results from the COPILOT study. Journal of Hepatology, 42: 40 [abstract 95].

    Google Scholar 

  • Davis, G.L. (2002). Monitoring of viral levels during therapy of hepatitis C. Hepatology, 36 (Suppl. 1): S145–151.

    Article  PubMed  Google Scholar 

  • Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J., Albrecht, J. (2003). Early virological response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38: 645–652.

    Article  PubMed  CAS  Google Scholar 

  • Dieterich, D.T., Spivak J.L. (2003a). Hematologic disorders associated with hepatitis C virus infection and their management. Clinical Infectious Diseases, 37 : 533–541.

    Article  CAS  Google Scholar 

  • Dieterich, D.T., Wassermen, R., Bräu, N., Hassanein, T.I., Bini, E.J., Bowers, P.J., Sulkowski, M.S. (2003b). Once-weekly epoietin alpha improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alpha. American Journal of Gastroenterology, 98: 2491–2499.

    CAS  Google Scholar 

  • Drusano, G.L., Preston, S.L. (2004). A 48-week duration of therapy with pegylated interferon a2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. Journal of Infectious Diseases, 189: 964–970.

    Article  PubMed  CAS  Google Scholar 

  • Dumortier, J., Scoazec, J.Y., Chevallier, P., Boillot, O. (2004). Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alpha-2b and ribavirin combination. Journal of Hepatology, 40: 669–674.

    Article  PubMed  CAS  Google Scholar 

  • Everson, G.T. (2004). Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Reviews in Gastroenterological Disorders, 4 (Suppl. 1): S31–S38.

    PubMed  Google Scholar 

  • Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J.T., Thomas, H., Njapoum, C., Casarin, C., Bonetti, P., Fuschi, P., Basho, J., Tocco, A., Bhalla, A., Galassini, R., Noventa, F., Schalm, S.W., Realdi, G. (1997). Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology, 112: 463–472.

    Article  PubMed  CAS  Google Scholar 

  • Fattovich, G., Pantalena, M., Zagni, I., Realdi, G., Schalm, S.W., Christensen, E. European Concerted Action on Viral Hepatitis (EUROHEP) (2002). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology, 97: 2886–2895.

    Article  PubMed  Google Scholar 

  • Ferenci, P. (2004). Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetics studies. Journal of Antimicrobial Chemoterapy, 43 : 15–18.

    Google Scholar 

  • Ferenci, P., Fried, M.W., Shiffman, M.L., Smith, C.I., Marinos, G., Goncales, F.L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Chaneac, M., Reddy, K.R. (2005). Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alpha-2a (40kd)/ribavirin. Journal of Hepatology, 43: 425–433.

    Article  PubMed  CAS  Google Scholar 

  • Forman, L.M., Lewis, J.D., Berlin, J.A, Feldman, H.I., Lucey, M.R. (2002). The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology, 122: 889–896.

    Article  PubMed  Google Scholar 

  • Foruny, J.R., Blázquez, J., Moreno, A., Bárcena, R., Gil-Grande, L., Quereda, C., Pérez-Elías, M.J., Moreno, J., Sánchez, J., Muriel, A., Rodriguez-Sagrado, M.A., Moreno, S. (2005). Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. European Journal of Gastroenterology and Hepatology , 17: 1157–1164.

    Article  PubMed  CAS  Google Scholar 

  • Foruny, J.R., Bárcena, R., Moreno, A., Blázquez, J., Manzano, R., Gil-Grande, L.A., Moreno, A., Nuño, J. (2006). Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization. Transplantation, 82: 289–290.

    Article  PubMed  Google Scholar 

  • Fried, M.W. (2002). Side effects of therapy of hepatitis C and their management. Hepatology , 36 (Suppl. 1): S237–S244.

    Article  PubMed  Google Scholar 

  • Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002). Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. W2Ti New England Journal of Medicine , 347: 975–982.

    Article  CAS  Google Scholar 

  • Fuster, D., Planas, R., González, J., Force, L., Cervantes, M., Vilaro, J., Roget, M., García, I., Pedrol, E., Tor, J., Ballesteros, A.L., Salas, A., Sirera, G., Videla, S., Clotet, B., Tural, C. (2006). Results of a study of prolonging treatment with pegylated interferon-alpha-2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antiviral Therapy, 11: 473–482.

    PubMed  CAS  Google Scholar 

  • Gane, E. (2002). Treatment of recurrent hepatitis C. Liver Transplantation, 8 (Suppl.): S28–S37.

    Article  PubMed  Google Scholar 

  • Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J.C., Hirschel, B., Janin, P., Francioli, P., Flepp, M., Telenti, A. (2000). Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co-infection: the Swiss HIV Cohort Study. Lancet, 356: 1800–1805.

    Article  PubMed  CAS  Google Scholar 

  • Heathcote, E.J. (2003). Treatment considerations in patients with hepatitis C and cirrhosis. Journal of Clinical Gastroenterology, 37: 395–398.

    Article  PubMed  Google Scholar 

  • Hadziyannis, S.J., Sette, H. Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H. Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M., PEGAYS International Study Group (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomzed study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140: 346–355.

    PubMed  CAS  Google Scholar 

  • Hayashi, N., Takehara, T. (2006). Antiviral therapy for chronic hepatitis C: past, present, and future. Journal of Gastroenterology, 41: 17–27.

    Article  PubMed  Google Scholar 

  • Hoofnagle, J.H., Mullen, K.D., Jones, D.B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J.G., Park, Y., Jones, E.A. (1986). Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. New England Journal of Medicine, 315: 1575–1578.

    Article  PubMed  CAS  Google Scholar 

  • Höroldt, B., Haydon, G., O’Donnell, K., Dudley, T., Nightingale, P., Mutimer, P. (2006). Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver International, 26: 650–659.

    Article  PubMed  CAS  Google Scholar 

  • Jacobson, I.M., Brown, R.S., Freilich, B., Afdhal, N., Kwo, P., Santoro, J., Becker, S., Wakil, A., Pound, D., Godofsky, E., Strauss, R., Bernstein, D., Flamm, S., Bala, N., Araya, V., Davis, M., Monsour, H., Vierling, J., Regenstein, F., Balan, V., Dragutsky, M., Epstein, M., Herring, R.W., Rubin, R., Galler, G., Pauli, M.P., Griffel, L.H., the WIN-RS Group (2005). Weight-based ribavirin dosing increases sustained viral response in patients with chronic hepatitis C: final results of the WIN-R study, a US community based trial. Hepatology, 42 (Suppl. 1): Abstract LB03.

    Google Scholar 

  • Jensen, D.M., Marcellin, P. (2005). The rationale and design of the REPEAT study: a phase III, randomized clinical trial of peginterferon alpha-2a (40kDa) plus ribavirin in non-responders to peginterferon alpha-2b (12kDa) plus ribavirin. European Journal of Gastroenterology and Hepatology, 17: 899–904.

    Article  PubMed  CAS  Google Scholar 

  • Jensen, D.M., Morgan, T.R., Marcellin, P., Pockros, P.J., Reddy, K.R., Hadziyannis, S.J., Ferenci, P., Ackrill, A.M., Willems, B. (2006). Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon a-2a (40kd)/ribavirin therapy. Hepatology, 43: 954–960.

    Article  PubMed  CAS  Google Scholar 

  • Laguno, M., Murillas, J., Blanco, J.L., Martínez, E., Miquel, R., Sánchez-Tapias, J.M., Bargallo, X., García-Criado, A., de Lazzari, E., Larrousse, M., Leon, A., Lonca, M., Milinkovic, A., Gatell, J.M., Mallolas, J. (2004). Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS, 18: F27–F36.

    Article  PubMed  CAS  Google Scholar 

  • Lee, W.M., Dienstag, J.L., Lindsay, K.L., Lok, A.S., Bonkovsky, H.L., Shiffman, M.L., the HALT-C Trial Group (2004). Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.Controlled Clinical Trials, 25: 472–492.

    Article  PubMed  CAS  Google Scholar 

  • Maddison, F.E. (1973). Embolic therapy for hypersplenism. Investigative Radiology, 8: 280–281.

    Article  Google Scholar 

  • Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K. (2001). Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958–965.

    Article  PubMed  CAS  Google Scholar 

  • Manns, M.P., Wedemeyer, H., Cornberg, M. (2006). Treating viral hepatitis C: efficacy, side effects, and complications. Gut, 55: 1350–1359.

    Article  PubMed  CAS  Google Scholar 

  • Martinot-Peignoux, M., Comanor, L., Minor, J.M., Ripault, M.P., Pham, B.N., Boyer, N., Castelnau, C., Giuily, N., Hendricks, D., Marcellin, P. (2006). Accurate model predicting sustained reponse at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. Journal of Viral Hepatitis, 13: 701–707.

    Article  PubMed  CAS  Google Scholar 

  • McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K. (1998). Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 339: 1485–1492.

    Article  PubMed  CAS  Google Scholar 

  • McHutchison, J.G., Manns, M., Patel, K., Poynard, T., Lindsay, K.L., Trepo, C., Dienstag, J., Lee, W.M., Mak, C., Garaud, J.J, Albrecht, J.K., International Hepatitis Interventional Therapy Group (2002). Adherence to combination therapy enhances sustained virological response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 123: 1061–1069.

    Article  PubMed  CAS  Google Scholar 

  • McHutchison, J.G., Afdhal, N., Shiffman, M.L., Gordon, S., Mills, P., Sigal, S., Midwinter, D., Campbell, F.M., Williams, D., Theodore, D. (2006). Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV associated thrombocytopenia: preliminary results from a phase II dose-ranging study. Program and abstracts of the 41st. Annual Meeting of the European Association for the Study of the Liver. Abstract 745.

    Google Scholar 

  • Miró, J.M., Laguno, M., Moreno, A., Rimola, A., the Hospital Clinic OLT in HIV Working Group (2006). Management of end stage liver disease (ESLD): what is the current role of orthotropic liver transplantation (OLT)? Journal of Hepatology, 44 (Suppl.): S140–S145.

    Article  PubMed  Google Scholar 

  • Miró, J.M., Montejo, M., Vargas, V., Rimola, A., Rafecas, A., Miralles, P., Fortún, J., Blanes, M., de la Torre, J., Pons, J.A., the Spanish LT in HIV-Infected Patients Working Group (2006). Spanish cohort of HIV-infected patients with orthotropic liver transplantation (OLT): evaluation of 50 cases in the highly active antiretroviral (HAART) era (2002-2005). In Program and Abstracts of the 13 th Conference on Retroviruses and Opportunistic Infections, abstract 875.

    Google Scholar 

  • Moreno, A., Bárcena, R., Blázquez, J., Quereda, C., Gil-Grande, L., Sánchez, J., Moreno, L., Pérez-Elías, M.J., Antela, A., Moreno, J., del Campo, S., Moreno, S. (2004a). Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV-HCV patients prior to peg-interferon and ribavirin. Antiviral Therapy, 9: 1027–1030.

    Google Scholar 

  • Moreno, A., Quereda, C., Moreno, L., Pérez-Elías, M.J., Muriel, A., Casado, J.L., Antela, A., Dronda, F., Navas, E., Bárcena, R., Moreno, S. (2004b). High rate of didanosine-related mitochondrial toxicity in HIV/HCV co-infected patients receiving ribavirin. Antiviral Therapy, 9: 133–138.

    CAS  Google Scholar 

  • Moreno, A., Bárcena, R., García-Garzón, S., Muriel, A., Quereda, C., Moreno, L., Mateos, M.L., Fortún, J., Martín-Dávila, P., García, M., Blesa, C., Otón, E., Moreno, A., Moreno, S. (2005). HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-INF-α-2b/ribavirin. Journal of Hepatology, 43: 783–790.

    Article  PubMed  CAS  Google Scholar 

  • Moreno, A., Bárcena, R., García-Garzón, S., Moreno, L., Quereda, C., Muriel, A., Zamora, J., Mateos, M.L., Pérez-Elías, M.J., Antela, A., Diz, S., Moreno, A., Moreno, S. (2006). Viral kinetics and early prediction of nonresponse to peg-IFN-α-2b plus ribavirin in HCV genotype 1/4 according to HIV serostatus. Journal of Viral Hepatitis, 13: 466–473.

    Article  PubMed  CAS  Google Scholar 

  • Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J., Perelson, A.S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science , 282: 103–107.

    Article  PubMed  CAS  Google Scholar 

  • N’Kontchou, G., Seror, O., Bourcier, V., Mohand, D., Ajavon, Y., Castera, L., Grando-Lemaire, V.,Ganne-Carrie, N., Sellier, N., Trinchet, J.C., Beaugrand, M. (2005). Partial splenic embolization in patients with cirrhosis: efficacy, tolerance, and long-term outcome in 32 patients. European Journal of Gastroenterology and Hepatology, 17: 179–184.

    Article  PubMed  Google Scholar 

  • Otón, E., Bárcena, R., Moreno-Planas, J.M., Cuervas-Mons, V., Moreno-Zamora, A., Barrios, C., García-Garzón, S., Moreno, A., Boullosa-Graña, E., Rubio-González, E., García-González, M., Blesa, C., Mateos, M.L. (2006). Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. American Journal of Transplantation, 6: 2348–2355.

    Article  PubMed  CAS  Google Scholar 

  • Pälsson, B., Hallen, M., Forsberg-Mandahl, A.M., Alwmark, A. (2003). Partial splenic embolization—long-term outcome. Langenbecks Archives of Surgery, 387: 421–426.

    Google Scholar 

  • Pälsson, B., Verbaan, H. (2005). Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. European Journal of Gastroenterology and Hepatology, 17: 1153–1155.

    Article  PubMed  Google Scholar 

  • Pawlotsky, J.M. (2006). Therapy of hepatitis C: from empiricism to eradication. Hepatology, 43: S207–S220.

    Article  PubMed  CAS  Google Scholar 

  • Pawlotsky, J.M., Hezode, C., Pellegrin, B., Soulier, A., von Wagner, M., Brouwer, J.T., Missale, G,, Germanidis, G., Lurie, Y., Negro, F., Esteban, J., Hellstrand, K., Ferrari, C., Zeuzem, S., Schalm, S.W., Neumann, A.U.. (2002). Early HCV genotype 4 replication kinetics during treatment with peginterferon alpha-2a (Pegasys)-ribavirin combination: a comparison with HCV genotypes 1 and 3 kinetics. Hepatology, 36 (Suppl.): 219A.

    Google Scholar 

  • Pineda, J.A., Romero-Gómez, M., Diaz-García, F., Girón-González, J.A., Montero, J.L., Torre-Cisneros, J., Andrade, R.J., Gonzalez-Serrano, M., Aguilar, J., Aguilar-Guisado, M., Navarro, J.M., Salmerón, J., Caballero Granado, F.J., García-García, J.A., Grupo Andaluz para el Estudio de las Enfermedades Infecciosas; Grupo Andaluz para el Estudio del Hígado (2005). HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology, 41: 779–789.

    Article  PubMed  Google Scholar 

  • Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. (1998). Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet, 352: 1426–1432.

    Article  PubMed  CAS  Google Scholar 

  • Rios, R., Sangro, B., Herrero, I., Quiroga, J., Prieto, J. (2005). The role of thrombopoetin in the thrombocytopenia of patients with liver cirrhosis. American Journal of Gastroenterology , 100: 1311–1316.

    Article  PubMed  CAS  Google Scholar 

  • Sakata, K., Hirai, K., Tanikawa, K. (1996). A long-term investigation of transcatheter splenic arterial embolization for hypersplenism. Hepatogastroenterology, 43: 309–318.

    PubMed  CAS  Google Scholar 

  • Salmon-Ceron, D., Lewden, C., Morlat, P., Bevilacqua, S., Jougla, E., Bonnet, F., Heripret, L., Costagliola, D., May, T., Chene, G., The Mortality 2000 Study Group (2005). Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. Journal of Hepatology, 42: 799–805.

    Article  PubMed  CAS  Google Scholar 

  • Sánchez-Tapias, J.M., Diago, M., Escartín, P., Enríquez, J., Romero-Gómez, M., Bárcena, R., Crespo, J., Andrade, R., Martínez-Bauer, E., Pérez, R., Testillano, M., Planas, R., Solá, R., García-Bengoechea, M., García-Samaniego, J., Muñoz-Sánchez, M., Moreno-Otero, R. (2006). Peginterferon-alpha-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology, 131: 451–460.

    Article  PubMed  CAS  Google Scholar 

  • Sangiovanni, A., Pratti, G.M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., Del Ninno, E., Morabito, A., Colombo, M. (2006). The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology, 43: 1303–1310.

    Article  PubMed  Google Scholar 

  • Sangro, B., Bilbao, I., Herrero, I., Corella, C., Longo, J., Beloqui, O., Ruiz, J., Zozaya, J.M., Quiroga, J., Prieto, J. (1993). Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology, 18: 309–314.

    Article  PubMed  CAS  Google Scholar 

  • Sarrazin, C., Teuber, G., Kokka, R., Rabenau, H., Zeuzem, S. (2000). Detection of residual hepatitis C virus RNA by transcription mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology, 32: 818–823.

    Article  PubMed  CAS  Google Scholar 

  • Serfaty, L., Aumaitre, H., Chazouilleres, O., Bonnand, A.M., Rosmorduc, O., Poupon, R.E., Poupon, R. (1998). Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology, 27: 1435–1440.

    Article  PubMed  CAS  Google Scholar 

  • Shiffman, M.L., Price, A., Hubbard, S., Wilson, M., Salvatori, J., Sterling, R.K., Stravitz, R.T., Luketic, V.A., Sanyal, A.J. (2005). Treatment of chronic hepatitis C virus genotype 1 with peginterferon alpha-2b, high weight based dose ribavirin and epoietin-alpha enhances sustained virological response (abstr). Hepatology, A55.

    Google Scholar 

  • Solá, R., Tural, C., Rubio, R., Santín, M., Fuster, D., Moreno, S., Berenguer, J., González, J., Clotet, B., Planas, R. (2005). Lack of benefit of an induction dose of peginterferon alpha2a on early hepatitis C virus kinetics in HIV/HCV coinfected patients: results from the CORAL-1 Pilot, Multicenter Study. In program and abstracts of the 45 th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC): abstract LB H-416b.

    Google Scholar 

  • Soriano, V. (2006). Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates. Journal of Hepatology, 44 (Suppl.): S44–S48.

    Article  PubMed  CAS  Google Scholar 

  • Soriano, V., Puoti, M., Sulkowski, M., Mauss, S., Cacoub, P., Cargnel, A., Dieterich, D., Hatzakis, A., Rockstroh, J. (2004). Care of patients with hepatitis C and HIV co-infection: updated recommendations from the HIV-HCV International Panel. AIDS, 17: 1–12.

    Article  Google Scholar 

  • Soto, B., Sánchez-Quijano, A., Rodrigo, L., del Olmo, J.A., García-Bengoechea, M., Hernández-Quero, J., Rey, C., Abad, M.A., Rodriguez, M., Sales Gilabert, M., González, F., Miron, P., Caruz, A., Relimpio, F., Torronteras, R., Leal, M., Lissen, E. (1997). Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. Journal of Hepatology, 26: 1–5.

    Article  PubMed  CAS  Google Scholar 

  • Strader, D.B., Wright, T., Thomas, D.L., Seef, L.B. (2004). American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology, 39: 1147–1171.

    Article  PubMed  Google Scholar 

  • Tajiri, T., Onda, M., Yoshida, H., Mamada, Y., Taniai, N., Kumazaki, T. (2002). Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology, 49: 1445–1448.

    PubMed  Google Scholar 

  • Terrault, N.A. (2003). Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transplantation, 9 (Suppl.): 95–100. Terrault, N.A., Berenguer, M. (2006). Treating hepatitis C infection in liver transplant recipients. Liver Transplantation, 12: 1192–1204.

    Google Scholar 

  • Torriani, F.J., Rodriguez-Torres, M., Rockstroh, J.K., Lissen, E., González-García, J., Lazzarin, A,, Carosi, G., Sasadeuz, J., Katlama, C., Montaner, J., Sette, H. Jr., Passe, S., De Pamphilis, J., Duff, F., Schrenk, U.M., Dieterich, D.T., APRICOT Study Group (2004). Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine, 351: 438–450.

    Article  PubMed  CAS  Google Scholar 

  • Vallet-Pichard, A., Pol, S. (2006). Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. Journal of Hepatology, 44 (Suppl.): S28–S34.

    Article  PubMed  Google Scholar 

  • Vujic, I., Lauver, J.W. (1981). Severe complications from partial splenic embolization in patients with liver failure. British Journal of Radiology, 54 : 492–495.

    PubMed  CAS  Google Scholar 

  • Wiesner, R.H., Sorrell, M., Villamil, F. (2003). Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on liver transplantation and hepatitis C. Liver Transplantation, 9 (Suppl.): S1–S9.

    Article  PubMed  Google Scholar 

  • Zeuzem, S. (2000). Treatment of chronic hepatitis C virus infection in patients with cirrhosis. Journal of Viral Hepatitis, 7: 327–334.

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y., Cianciara, J., Ibranyi, E., Weiland, O., Noviello, S., Brass, C., Albretch, J. (2006). Efficacy of 24 weeks treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 44: 97–103.

    Article  PubMed  CAS  Google Scholar 

  • Zylberberg, H., Pol, S. (1996). Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clinical Infectious Diseases, 23 : 1117–1125.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Infectious Diseases,Hospital Ramón y Cajal, Carretera de Colmenar Km 9,1, 28034 Madrid, Spain

    Ana Moreno MD,PhD

Authors
  1. Ana Moreno MD,PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rafael Bárcena
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carmen Quereda
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Bari and National Institute for Digestive Disease, Castellana Grotte, Bari, Italy

    Emilio Jirillo

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Moreno, A., Bárcena, R., Quereda, C. (2008). Treatment of Chronic Hepatitis C in “Difficult-to-Treat” Patients in the Clinical Setting. In: Jirillo, E. (eds) Hepatitis C Virus Disease. Springer, New York, NY. https://doi.org/10.1007/978-0-387-71376-2_10

Download citation

Publish with us

Policies and ethics

Search

Navigation